A Phase IIIb, Open-label, Local, Multicenter Study of the Molecular Features of Postmenopausal Women With Hormone Receptor-positive (HR+) HER2-negative Advanced Breast Cancer on First-line Treatment With Ribociclib and Letrozole
Phase of Trial: Phase III
Latest Information Update: 07 Sep 2018
At a glance
- Drugs Letrozole (Primary) ; Ribociclib (Primary)
- Indications Advanced breast cancer
- Focus Pharmacogenomic; Registrational; Therapeutic Use
- Acronyms BioItaLEE
- Sponsors Novartis Pharmaceuticals
- 31 Aug 2018 Biomarkers information updated
- 28 Aug 2018 Status changed from not yet recruiting to recruiting.
- 27 Mar 2018 Planned initiation date changed from 1 Feb 2018 to 30 Apr 2018.